Your browser doesn't support javascript.
loading
MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species.
Roider, Elisabeth; Lakatos, Alexandra I T; McConnell, Alicia M; Wang, Poguang; Mueller, Alina; Kawakami, Akinori; Tsoi, Jennifer; Szabolcs, Botond L; Ascsillán, Anna A; Suita, Yusuke; Igras, Vivien; Lo, Jennifer A; Hsiao, Jennifer J; Lapides, Rebecca; Pál, Dorottya M P; Lengyel, Anna S; Navarini, Alexander; Okazaki, Arimichi; Iliopoulos, Othon; Németh, István; Graeber, Thomas G; Zon, Leonard; Giese, Roger W; Kemeny, Lajos V; Fisher, David E.
Afiliação
  • Roider E; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, USA. Elisabeth.Roider@usb.ch.
  • Lakatos AIT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA. Elisabeth.Roider@usb.ch.
  • McConnell AM; Department of Dermatology, University Hospital of Basel, Basel, Switzerland. Elisabeth.Roider@usb.ch.
  • Wang P; HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
  • Mueller A; Department of Physiology, Semmelweis University, Budapest, Hungary.
  • Kawakami A; Department of Dermatology, Venereology, and Dermatooncology, Semmelweis University, Budapest, Hungary.
  • Tsoi J; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Massachusetts and the Howard Hughes Medical Institute, Boston, USA.
  • Szabolcs BL; Department of Pharmaceutical Sciences, Department of Chemistry and Chemical Biology, and Barnett Institute, Bouve College, Northeastern University, Boston, MA, 02115, USA.
  • Ascsillán AA; Department of Dermatology, University Hospital of Basel, Basel, Switzerland.
  • Suita Y; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Igras V; Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
  • Lo JA; UCLA Metabolomics Center, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
  • Hsiao JJ; HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
  • Lapides R; Department of Physiology, Semmelweis University, Budapest, Hungary.
  • Pál DMP; Department of Dermatology, Venereology, and Dermatooncology, Semmelweis University, Budapest, Hungary.
  • Lengyel AS; HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
  • Navarini A; Department of Physiology, Semmelweis University, Budapest, Hungary.
  • Okazaki A; Department of Dermatology, Venereology, and Dermatooncology, Semmelweis University, Budapest, Hungary.
  • Iliopoulos O; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Németh I; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Graeber TG; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Zon L; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Giese RW; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Kemeny LV; Robert Larner, College of Medicine at the University of Vermont, Burlington, USA.
  • Fisher DE; HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
Sci Rep ; 14(1): 21527, 2024 09 14.
Article em En | MEDLINE | ID: mdl-39277608
ABSTRACT
Microphthalmia-associated transcription factor (MITF) is a master regulator of melanocyte function, development and plays a significant role in melanoma pathogenesis. MITF genomic amplification promotes melanoma development, and it can facilitate resistance to multiple therapies. Here, we show that MITF regulates a global antioxidant program that increases survival of melanoma cell lines by protecting the cells from reactive oxygen species (ROS)-induced damage. In addition, this redox program is correlated with MITF expression in human melanoma cell lines and patient-derived melanoma samples. Using a zebrafish melanoma model, we show that MITF decreases ROS-mediated DNA damage in vivo. Some of the MITF target genes involved, such as IDH1 and NNT, are regulated through direct MITF binding to canonical enhancer box (E-BOX) sequences proximal to their promoters. Utilizing functional experiments, we demonstrate the role of MITF and its target genes in reducing cytosolic and mitochondrial ROS. Collectively, our data identify MITF as a significant driver of the cellular antioxidant state.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peixe-Zebra / Regulação Neoplásica da Expressão Gênica / Espécies Reativas de Oxigênio / Fator de Transcrição Associado à Microftalmia / Isocitrato Desidrogenase / Melanoma Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peixe-Zebra / Regulação Neoplásica da Expressão Gênica / Espécies Reativas de Oxigênio / Fator de Transcrição Associado à Microftalmia / Isocitrato Desidrogenase / Melanoma Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article